Glycostem and Ghent University announced a license agreement on NK cell therapy technology
We are glad to announce that Glycostem and Ghent University have signed a license agreement on NK cell therapy technology.
Read moreThe future looks bright!
In the winter edition of Biotech NEWS & Life Sciences, Brigitte Drees talks about Pivot Park's future plans.
Read more
Digital kick-off of the policy framework economy 2030
On Wednesday, November 25, the province of North Brabant organized a digital kick-off of the policy framework economy 2030
Read more
Inprocess-LSP contributed successfully to Covid19 vaccine
The NanoFlowSizer is now used for the measurement of the particle size
Read more
Pharming announces commitment to building a new downstream manufacturing facility at Pivot Park
At Pivot Park, Pharming will move into a new, sustainable, five-story building with a total floor space of approximately 4,000 m².
Read moreLead Pharma enters into a Research Collaboration with Roche
Lead Pharma enters into a Research Collaboration and License Agreement with Roche.
Read morePharmaCytics and Madam Therapeutics announce collaboration to develop a new class of oral anti-biotics
PharmaCytics and Madam Therapeutics announce collaboration to develop a new class of oral anti-biotics.
Read more
Press release Glycostem
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
Read more